Published in Genes Chromosomes Cancer on August 01, 2007
The H3K36 demethylase Jhdm1b/Kdm2b regulates cell proliferation and senescence through p15(Ink4b). Nat Struct Mol Biol (2008) 3.80
The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma. Br J Cancer (2008) 0.81
The evolution of Sex-linked barring alleles in chickens involves both regulatory and coding changes in CDKN2A. PLoS Genet (2017) 0.75
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol (2009) 8.68
Magnetic domain-wall racetrack memory. Science (2008) 8.24
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med (2014) 5.43
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA (2011) 4.84
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet (2009) 3.89
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet (2007) 3.63
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature (2011) 3.53
ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res (2005) 3.44
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet (2008) 3.41
Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol (2005) 3.20
Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst (2006) 3.17
Chiral spin torque at magnetic domain walls. Nat Nanotechnol (2013) 2.98
Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol (2009) 2.94
Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1. Nat Genet (2005) 2.92
Telemedical wound care using a new generation of mobile telephones: a feasibility study. Arch Dermatol (2005) 2.91
Dermoscopic examination of nail pigmentation. Arch Dermatol (2002) 2.83
In silico analysis of missense substitutions using sequence-alignment based methods. Hum Mutat (2008) 2.73
Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst (2002) 2.70
Current-controlled magnetic domain-wall nanowire shift register. Science (2008) 2.68
Myeloid cell differentiation arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation. J Exp Med (2008) 2.49
Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). BMJ (2012) 2.44
UV irradiation triggers ubiquitin-dependent degradation of p21(WAF1) to promote DNA repair. Cell (2003) 2.41
High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res (2006) 2.40
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
Genome-wide association study identifies three new melanoma susceptibility loci. Nat Genet (2011) 2.29
International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev (2003) 2.25
Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). J Natl Cancer Inst (2006) 2.25
Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res (2004) 2.17
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2009) 2.13
Dependence of current and field driven depinning of domain walls on their structure and chirality in permalloy nanowires. Phys Rev Lett (2006) 2.11
Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res (2002) 2.09
TP53 mutations in human skin cancers. Hum Mutat (2003) 2.07
Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie. J Clin Oncol (2004) 2.05
Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer. Am J Hum Genet (2009) 2.02
Incidence of DNA repair deficiency disorders in western Europe: Xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy. DNA Repair (Amst) (2008) 2.02
2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol (2009) 1.97
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res (2010) 1.90
The role of UV induced lesions in skin carcinogenesis: an overview of oncogene and tumor suppressor gene modifications in xeroderma pigmentosum skin tumors. Mutat Res (2005) 1.86
DICER1 mutations in familial multinodular goiter with and without ovarian Sertoli-Leydig cell tumors. JAMA (2011) 1.85
Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. J Clin Oncol (2007) 1.83
Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy. Oncogene (2004) 1.79
Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico/in vitro studies on BRCA1 and BRCA2 variants. Hum Mutat (2012) 1.77
Diagnosis and management of nail pigmentations. J Am Acad Dermatol (2007) 1.73
High frequency of germline SUFU mutations in children with desmoplastic/nodular medulloblastoma younger than 3 years of age. J Clin Oncol (2012) 1.71
Germline BAP1 mutations predispose to renal cell carcinomas. Am J Hum Genet (2013) 1.69
In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood (2002) 1.66
ERCC2/XPD gene polymorphisms and cancer risk. Mutagenesis (2002) 1.65
Molecular analysis of mutations in DNA polymerase eta in xeroderma pigmentosum-variant patients. Proc Natl Acad Sci U S A (2002) 1.63
Determining the effectiveness of High Resolution Melting analysis for SNP genotyping and mutation scanning at the TP53 locus. BMC Genet (2009) 1.63
A prevalent mutation with founder effect in xeroderma pigmentosum group C from north Africa. J Invest Dermatol (2010) 1.61
DNA polymerase eta is involved in hypermutation occurring during immunoglobulin class switch recombination. J Exp Med (2004) 1.59
DNA repair: from molecular mechanism to human disease. DNA Repair (Amst) (2006) 1.56
Time required for a complete skin examination with and without dermoscopy: a prospective, randomized multicenter study. Arch Dermatol (2008) 1.53
Role of DNA polymerase eta in the UV mutation spectrum in human cells. J Biol Chem (2003) 1.53
Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome (PNAS). Genes Dev (2011) 1.52
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin Cancer Res (2011) 1.52
Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2011) 1.51
XPD mutations prevent TFIIH-dependent transactivation by nuclear receptors and phosphorylation of RARalpha. Cell (2002) 1.51
Dermoscopic evaluation of amelanotic and hypomelanotic melanoma. Arch Dermatol (2008) 1.51
Brain magnetic resonance imaging in patients with Cowden syndrome. Medicine (Baltimore) (2005) 1.50
Sarcoidosis and melanoma: a referral center study of 1,199 cases. Dermatology (2009) 1.49
Distinctive features of melanoma and its management in elderly patients: a population-based study in France. JAMA Dermatol (2013) 1.49
Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3. Nat Genet (2011) 1.46
Variations in management of stage I to stage III cutaneous melanoma: a population-based study of clinical practices in France. Arch Dermatol (2008) 1.45
Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening study. Breast Cancer Res (2011) 1.45
The CDK4-pRB-E2F1 pathway controls insulin secretion. Nat Cell Biol (2009) 1.45
The furrow ink test: a clue for the dermoscopic diagnosis of acral melanoma vs nevus. Arch Dermatol (2008) 1.44
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc Natl Acad Sci U S A (2007) 1.43
Apoptotic induction by anti-CD20 antibodies in chronic lymphocytic leukemia: comparison of rituximab and obinutuzumab. Leuk Lymphoma (2013) 1.43
ERCC2 /XPD gene polymorphisms and lung cancer: a HuGE review. Am J Epidemiol (2005) 1.41
Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2010) 1.41
Role of DNA polymerases eta, iota and zeta in UV resistance and UV-induced mutagenesis in a human cell line. DNA Repair (Amst) (2008) 1.40
[Human dirofilariasis: 3 cases in the south of France]. Presse Med (2007) 1.39
[Revocation of the BRCA1 patents by the European Office of Patents: a victory over a rights abuse]. Bull Cancer (2005) 1.38
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res (2012) 1.38
DNA repair gene XRCC2 and XRCC3 polymorphisms and susceptibility to cancers of the upper aerodigestive tract. Int J Cancer (2004) 1.37
Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Société Française d'Oncologie Pédiatrique. J Clin Oncol (2003) 1.36
GLP-1 mediates antiapoptotic effect by phosphorylating Bad through a beta-arrestin 1-mediated ERK1/2 activation in pancreatic beta-cells. J Biol Chem (2009) 1.36
mda-9/Syntenin: a positive regulator of melanoma metastasis. Cancer Res (2005) 1.35
Frequency of dermoscopic nevus subtypes by age and body site: a cross-sectional study. Arch Dermatol (2011) 1.34
Classification of missense substitutions in the BRCA genes: a database dedicated to Ex-UVs. Hum Mutat (2011) 1.31
Human DNA polymerase iota protects cells against oxidative stress. EMBO J (2008) 1.31
Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol (2009) 1.30